Evidence map›Paper›PMID 33704660›Full record

ReviewMetabolic brain disease2021

Modulating neuroinflammation in neurodegeneration-related dementia: can microglial toll-like receptors pull the plug?

Rohit Kumar Tiwari, Afrasim Moin, Syed Mohd Danish Rizvi, Syed Monowar Alam Shahid, Preeti Bajpai

Abstract readReview
PubMed Publisher
In one paragraph

Review in Metabolic brain disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. P2Y1 receptor in Alzheimer's disease.Neural regeneration research · 2025
    Article
  3. Protective Assessment of Novel (BNC Formulation) against Brain Tumor.Recent patents on anti-cancer drug discovery · 2025
    Article
  4. Review
  5. Article
  6. Endophytic fungi: a potential source for drugs against central nervous system disorders.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023
    Review
  7. Frontiers in pharmacology · 2022
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Rohit Kumar TiwariDepartment of Biosciences, Integral University, Kursi Road, Lucknow, Uttar Pradesh, 226026, India.ORCID https://orcid.org/0000-0001-8215-633X
Afrasim MoinDepartment of Pharmaceutics, College of Pharmacy, University of Hail, Hail, Kingdom of Saudi Arabia.
Syed Mohd Danish RizviDepartment of Pharmaceutics, College of Pharmacy, University of Hail, Hail, Kingdom of Saudi Arabia.
Syed Monowar Alam ShahidDepartment of Biochemistry, College of Medicine, University of Hail, Hail, Kingdom of Saudi Arabia.
Preeti BajpaiDepartment of Zoology, School of Life Sciences, Mahatma Gandhi Central University, Motihari, Bihar, 845401, India. preetibajpai@mgcub.ac.in.ORCID http://orcid.org/0000-0001-9276-9324
University of Ha'il · SACentral University of South Bihar · INIntegral University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegeneration-associated dementia disorders (NADDs), namely Alzheimer and Parkinson diseases, are developed by a significant portion of the elderly population globally. Extensive research has provided critical insights into the molecular basis of the pathological advancements of these diseases, but an efficient curative therapy seems elusive. A common attribute of NADDs is neuroinflammation due to a chronic inflammatory response within the central nervous system (CNS), which is primarily modulated by microglia. This response within the CNS is positively regulated by cytokines, chemokines, secondary messengers or cyclic nucleotides, and free radicals. Microglia mediated immune activation is regulated by a positive feedback loop in NADDs. The present review focuses on evaluating the crosstalk between inflammatory mediators and microglia, which aggravates both the clinical progression and extent of NADDs by forming a persistent chronic inflammatory milieu within the CNS. We also discuss the role of the human gut microbiota and its effect on NADDs as well as the suitability of targeting toll-like receptors for an immunotherapeutic intervention targeting the deflation of an inflamed milieu within the CNS.

Indexed as

AnimalsBrainDementiaHumansInflammationMicrogliaNerve DegenerationToll-Like ReceptorsToll-Like ReceptorsAlzheimer diseaseHuman microbiomeImmunotherapyNeurodegenerationNeuroinflammationParkinson diseaseToll-like receptors

Identifiers

PMID33704660
OpenAlexW3134726143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.